STAT reports that Servier has announced a surprise setback for a drug in development for a form of muscular dystrophy with no current treatment. The drug, valued at $1.55 billion, failed its first major clinical test according to the company.
This development matters to pharma and biotech executives because it highlights the risk and uncertainty in rare disease drug pipelines. Companies with similar assets may face renewed scrutiny from investors and regulators. The news could prompt a review of clinical trial strategies and portfolio priorities across the sector.
